Module 1: Driving forwards with immunotherapy in NSCLC – latest advances - ESMO-IO 2018
Learning Objectives Introduction

Introduction

Watch an internationally renowned faculty discuss the changing treatment paradigms in advanced NSCLC, including the current and future role of immunotherapy.

Dr. Maria Chiara Garassino and Dr. Maurice Pérol, discuss recent developments in clinical research and how these can be translated into clinical practice. Professor Enriqueta Felip and Professor Sanjay Popat (Chair) then provide insight on the future management of patients with advanced NSCLC using clinical case studies.

The information in this activity is intended for oncologists, nurses, and other healthcare professionals involved in the treatment of patients with lung cancer.

This ACCME-accredited touchSATELLITE SYMPOSIUM was recorded live during the ESMO Immuno-Oncology Congress in December 2018. The live voting content is no longer active for this symposium.

Learning objectives

After watching this touchSATELLITE SYMPOSIUM, you should:

1 AMA PRA Category 1 Credits™
Date of original release: March 7, 2019
Date credits expire: March 7, 2020 

Back to Education Zone

touchSATELLITE SYMPOSIUM

Harnessing the power of immunotherapy in advanced non-small cell lung cancer:
how do we navigate the increasingly complex patient pathway without an oncogenic driver?

1 AMA PRA Category 1 Credits™
Date of original release: March 7, 2019
Date credits expire: March 7, 2020 

Module 1: Driving forwards with immunotherapy in NSCLC – latest advances

Dr. Marina Chiara Garassino, MD describes the latest clinical data for advanced NSCLC and how these results impact on clinical practice. She provides an overview of the available checkpoint inhibitors and their mechanisms of action, including data from key clinical trials investigating first-line options for patients with NSCLC without oncogenic driver mutations.

Key Learnings

Please test your knowledge about the information presented. The following questions will need to be completed to progress.

Q1. Blockade of PD-1/PD-L1 pathway using a fully humanized PD-1 or PD-L1 antagonistic monoclonal antibody has been shown to increase the number and functionality of tumour-specific T cells.

a) True
b) False

PD-1 expression is induced on activated T cells, and the interaction between PD-1 and one of its ligands on the surface of tumours leads to a diminished antitumor response and the loss of effector functions, including the ability of T cells to proliferate. By blocking this pathway with immune checkpoint inhibitors, anti-tumour immune responses can be restored.1

PD-1 expression is induced on activated T cells, and the interaction between PD-1 and one of its ligands on the surface of tumours leads to a diminished antitumor response and the loss of effector functions, including the ability of T cells to proliferate. By blocking this pathway with immune checkpoint inhibitors, anti-tumour immune responses can be restored.1

Next Question

You completed: Module 1: Driving forwards with immunotherapy in NSCLC – latest advances

REFERENCES